Codes ATC:
L04AB04
EMLc
Indication
Crohn disease site
Code ICD11:
DD70.Z
INN
Adalimumab
Type de médicament
Biological agent
Type de liste
Liste complémentaire
(EML)
(EMLc)
(EMLc)
Additional notes
EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars. EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.
Formulations
Parenteral > General injections > SC:
40 mg per 0.8 mL ;
40 mg per 0.4 mL ;
10 mg per 0.2 mL
(EMLc)
;
20 mg per 0.4 mL
(EMLc)
Historique des statuts LME
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
Renseignements sur le brevet
Main patents have expired but secondary patents might remain active in some jurisdictions. For more
information on specific patents and license status for developing countries visit www.MedsPal.org
Lire la suite
sur les brevets.
Résumé des preuves et recommandation du comité d'experts
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc.